LLY vs ABT
By Alex · Tickerpine
Eli Lilly and Company vs Abbott Laboratories, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | ABT |
|---|---|---|
| Price | $1,208.12 | $94.12 |
| Market cap | $1.08T | $163.94B |
| P/E ratio | 42.9 | 26.4 |
| ROE | 107.46% | 12.33% |
| Profit margin | 34.99% | 13.90% |
| Revenue growth | 55.50% | 7.80% |
| Dividend yield | 0.57% | 2.68% |
| Beta | 0.52 | 0.62 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs ABT in plain English
- LLY is the bigger company — about 6.6× the market cap of ABT.
- ABT is cheaper on earnings (P/E 26.4 vs 42.9).
- LLY earns a higher return on equity (107% vs 12%).
- LLY is growing revenue faster (56% vs 8%).
- ABT has the higher dividend yield (2.68% vs 0.57%).
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
ABT return calculator
See what $1,000 in Abbott Laboratories would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.